Drug Sales GrowthSales of innovative drugs, excluding collaboration revenue, saw strong growth of +28.2% YoY, totaling RMB7.9bn.
Financial PerformanceHansoh's FY24 performance was in line with expectations, reporting revenue of RMB12.26bn and attributable net income of RMB4.37bn.
Strategic PartnershipsHansoh further out-licensed one of its oral small molecule GLP-1R agonists to MSD through a blockbuster deal, indicating sustainable profit from overseas out-licensing deals.